In Brief
HLA-F can regulate immunity as an empty open conformer but whether or not HLA-F can present peptides is controversial.
Dulberger et al. show that HLA-F has
recently evolved an open-ended antigenbinding groove that facilitates presentation of uncharacteristically long peptides and that recognition of HLA-F by NKRs is tunable by peptide binding.
INTRODUCTION
Major histocompatibility complex (MHC) molecules allow the immune system to survey the health of virtually every cell in the body. The MHC fold is highly programmable and has been molded throughout evolution to create MHC molecules that are specialized for presentation of lipids, small molecule ligands, or peptides. MHC class I (MHC-I) molecules function by binding and displaying self and non-self peptides on the cell surface where they designate the cell as healthy, infected, or foreign. Leukocytes employ a diverse array of antigen receptors, such as T cell receptors (TCRs) and natural killer cell receptors (NKRs) , that perceive the information presented by MHC-I molecules to elicit the appropriate immune response (Adams and Luoma, 2013) .
While the MHC-Ia molecules (human leukocyte antigens [HLA] -A, -B, and -C) are ubiquitously expressed, the MHC-Ib molecules (HLA-E, -F, and -G) are much more specialized in terms of tissue localization, antigen presentation, and function. Because of their limited levels of polymorphism, the repertoire of peptides that MHC-Ib molecules present is greatly reduced (Braud et al., 1997) and they predominantly regulate immunity through TCR-independent interactions. HLA-E preferentially presents peptides derived from the leader sequences of other MHC-I molecules, serving as a sensor of MHC-I expression that protects against lysis via interactions with inhibitory NKRs in the CD94-NKG2 family . HLA-G is also quite specialized; it primarily presents endogenous peptides at the surface of trophoblasts lining the placenta (Clements et al., 2005) , which mostly lacks MHC-Ia expression (Ferreira et al., 2017) . At this maternal-fetal interface, HLA-G signals through activating and inhibitory NKRs in the killer-cell immunoglobulinlike receptor (KIR), leukocyte immunoglobulin-like receptor (LIR), and CD94-NKG2 receptor complex families to facilitate maternal tolerance and development of the fetus (Ferreira et al., 2017) . Studies have also shown that MHC-Ib molecules can be directly recognized by TCRs on regulatory (Jiang et al., 2010) and cytolytic (Romagnani et al., 2002) T cells.
While HLA-E and HLA-G have been well characterized functionally and structurally as antigen-presenting molecules, the role that HLA-F plays in regulating the immune system has remained enigmatic until recently. HLA-F has been implicated as a protective molecule in pregnancy (Burrows et al., 2016) and the peripheral nervous system, where HLA-F recognition by the inhibitory KIR3DL2 was shown to prevent motor neuron death in the development of amyotrophic lateral sclerosis (ALS) (Song et al., 2016) . It has also been demonstrated that recognition of HLA-F by the activating KIR3DS1 on NK cells elicits an anti-viral response that inhibits HIV-1 replication (Garcia-Beltran et al., 2016) . This ability to regulate immunity via KIR3DS1 greatly increases the clinical significance of HLA-F, in light of the broad range of other diseases where KIR3DS1 is implicated (Kö rner and Altfeld, 2012) .
The wide-ranging immunoregulatory capacity of HLA-F is becoming clear; however, our understanding of the underlying structural and biochemical properties that govern HLA-F function is limited. Molecular modeling and sequence alignment has predicted that HLA-F shares the highly conserved MHC fold but with a partially open-ended groove (Goodridge et al., 2010) . In the MHC-I family there are ten conserved residues that are critical for establishing the architecture of the groove and for specific interactions with peptide residues. Five of these ten residues are altered within the HLA-F groove, which has led to the prediction that HLA-F either does not present peptide or does so in a fundamentally divergent manner from other HLAs (Geraghty et al., 1990) . Meticulous studies have failed to elute canonical MHC-Ilike peptides from natively expressed HLA-F in human cell lines. Thus, it is generally thought that HLA-F does not present antigen (Goodridge et al., 2010; Wainwright et al., 2000) and instead may function as an empty, open conformer (OC) that heterodimerizes with other MHC-I molecules and lacks association with beta-2 microglobulin (b 2 m) (Goodridge et al., 2013) . However, there is evidence for dimerized HLA-F complexed with b 2 m on the cell surface of placental tissues during pregnancy (Hackmon et al., 2017) and small amounts of b 2 m-HLA-F have been extracted from cells (Goodridge et al., 2010) . Furthermore, HLA-F interacts with components of the transporter associated with antigen processing (TAP) peptide-loading complex (Lepin et al., 2000; Wainwright et al., 2000) . This suggests that HLA-F may exist in multiple isoforms with varying potential for peptide binding and recognition by antigen receptors.
Previous studies indicate that HLA-F can regulate immunity through direct interactions with NKRs. Like other MHC-I molecules, HLA-F binds NKRs from the LIR and KIR families: LIR1, LIR2 (Lepin et al., 2000) , KIR2DS4, KIR3DL2 (Goodridge et al., 2013) , KIR3DL1, and KIR3DS1 (Garcia-Beltran et al., 2016) . However, since these studies were conducted with denatured and refolded HLA-F, the possible contribution of bound peptide in these interactions has not been explored. The molecular mechanism for HLA-F recognition by NKRs is also entirely unclear as there have been no published studies on HLA-F structure.
Here, we present a molecular description of HLA-F and its recognition by an inhibitory NKR and elucidate the importance of peptide binding for differential NKR reactivity. Our structural, biochemical, and evolutionary analyses establish that HLA-F can exist as both an OC and as a bona fide peptide-presenting MHC molecule. Our cellular assays and binding studies confirm the functional significance of HLA-F and provide a model for how peptide binding modulates HLA-F recognition by activating and inhibitory NKRs. Altogether, these data have major implications for our understanding of how HLA-F functions as an immunoregulatory molecule.
RESULTS
The Crystal Structure of HLA-F Reveals Strong Evidence for a Unique Mode of Peptide Presentation The b 2 m-HLA-F fusion construct was produced in High Five (Hi5) cells via the baculovirus insect cell expression system and yielded crystals that diffracted to 2.62 Å . The structure of HLA-F was solved in two different space groups by molecular replacement with HLA-B27 (Madden et al., 1992) . Consistent with the high degree of structural homology in the MHC-I family, HLA-F adopts a conserved overall architecture and associates with b 2 m via a conventional interface ( Figure 1A ). At first glance, the antigen-binding groove of HLA-F is quite canonical; alignment with HLA-A2 and HLA-G yields root mean square deviations (RMSDs) of only 0.53 Å and 0.763 Å (Ca of residue 1-180) with 77% sequence identity ( Figure 1B ). The molecular landscape of the HLA-F groove, with a volume of 1,250 Å 3 , is more consistent with the peptide-presenting MHC-I molecules than the non-peptide-presenting MHC-like molecules, MICA and FcRN, which have collapsed grooves ( Figure 1C ).
Consistent with peptide presentation, 2F o -F c electron density and composite omit maps reveal a large continuous tube of electron density in the groove that is not attributed to any of the residues of HLA-F (Figure 2) . A peptide of approximately eight residues can be modeled into this extra density but due to the heterogeneous nature of bound peptides, the exact identities of the peptide side chains are unclear. Indeed, when interrogated via liquid chromatography-mass spectrometry (LC-MS), HLA-F produced in this system was found to contain 48 distinct peptides that did not originate from the HLA-F construct or a common contaminant, keratin (Table S2) . However, only one peptide hit the Hi5 source organism (Trichoplusia ni), likely because the protein database for Trichoplusia is small, consisting of only 216 protein sequences. Thermal denaturation revealed that peptide-loaded Hi5-derived HLA-F has a melting temperature (Tm) in line with the most stable MHC-I-peptide complexes observed ( Figure S1 ; Morgan et al., 1997) .
Due to the unique molecular landscape of the HLA-F groove, the placement of the bound peptide is distinct compared to how other MHC-I molecules present peptide. The canonical MHC-I binding pockets (A-F) described for HLA-A2 (Figure 2A ; Saper et al., 1991) that dictate specificity for interactions with peptide side chains are substantially altered in the HLA-F groove due to the substitution of five of the ten aforementioned highly conserved residues in MHC-I molecules ( Figure S2 ). These substitutions modify the electrostatic environment and hydrogenbonding network in the groove. Nonconservative amino acid alterations at two additional positions, G62W and G26E, result in an entirely blocked off A pocket which forces the unanchored N terminus of the peptide to snake up and out of the groove. In the absence of an N-terminal anchor, the central (P5) and C-terminal (P7 and P8) portions of the peptide are firmly anchored within the C, E, and F pockets via hydrogen bonds to the peptide backbone and side chains ( Figure 2C ). The central pocket (C) is formed by a pronounced substitution to a glycine at position 97, which is occupied by a tryptophan or bulky, charged residue in all other MHC-I molecules. The electron density of the peptide residue that is anchored deep within this pocket is evocative of a bulky residue such as a tryptophan but is also consistent with a post-translationally modified (PTM) side chain ( Figure 2C ). This residue is coordinated by the His114-His116 motif, which is reminiscent of the His-His motif seen in the groove of HLA-E (O'Callaghan and Bell, 1998) as well as those seen in the active sites of histidine phosphatases where they are essential for coordinating the substrate phosphate for catalysis.
HLA-F Presents Endogenous Peptides of a Length Distribution Reminiscent of MHC Class II Molecules
The crystal structure of HLA-F led us to question whether its divergent topography and peculiar peptide orientation would have ramifications on the size and types of peptides that HLA-F can present. To investigate HLA-F peptide presentation in human cells, we recombinantly expressed and purified soluble HLA-F from HEK293T (293T) cells for peptide elution analysis via mass spectrometry. Secreted 293T HLA-F has a melting curve that is consistent with those reported for other MHC-I molecules bound with endogenous peptides and expressed in a similar manner ( Figure S1 ; Fahnestock et al., 1992) .
MHC-Ia molecules bind an impressive variety of peptides (elution samples from a similar quantity of MHC-I contain > 5,000 peptides; Trolle et al., 2016) while peptide elution experiments from the more specialized MHC-Ib proteins typically identify significantly fewer peptides (Kraemer et al., 2015) . 2,679 peptide sequences were eluted from WT HLA-F produced in 293T cells and identified with high confidence by liquid chromatography-mass spectroscopy (LC-MS) (Table S3 ). In agreement with the structural evidence that HLA-F peptides are not constrained by the length of the groove, peptides eluted from Table S1 and Figure S1 .
HLA-F are much longer than the typical length of MHC-I peptides (8-10 residues). HLA-F peptides range from 7 residues to >30, peaking at 12 residues. This length distribution is more consistent with that of MHC-II molecules ( Figure 3A ; Bergseng et al., 2015) , which escape the length constraints imposed on peptides by having a groove that is open at both ends (Brown et al., 1993) . Consistent with the structural data showing that HLA-F peptides lack N-terminal anchors, the peptide motif analysis suggests that HLA-F is relatively unselective aside from a preference for a charged residue (such as an aspartate) at the most C-terminal position ( Figure 3B ). This C-terminal residue is firmly anchored via a hydrogen bond from T143 to the peptide backbone as well as two salt bridges from R84 to the peptide side chain and backbone ( Figure 2C ). This C-terminal anchoring strategy is unique to HLA-F, as all other MHC-I molecules have a tyrosine at position 84 that makes a single hydrogen bond with the C terminus of the peptide backbone.
While HLA-F largely conforms to the principles of MHC-I peptide presentation in terms of the source proteins sampled ( Figure S3 ), the 2D LC-MS data indicates that peptides bound by HLA-F have a high prevalence of PTMs, particularly phosphorylation ( Figure 3C ). These data, accompanied by the observation of the His-His motif in the C pocket, suggests that HLA-F may be able to accommodate a phosphorylated side chain deep in the center of the groove.
The R62W Substitution Converts HLA-F into a Peptide-Presenting Molecule
The peptide elution data prompted us to consider the evolutionary processes that led to such a divergent molecular landscape and mode of peptide presentation. Our analysis suggested that HLA-F peptide presentation evolved independently in the human and orangutan lineages with the convergent substitution of arginine 62 to tryptophan (R62W) ( Figure 4A ). This substitution, which is absent in chimpanzee, gorilla, and other primate versions of HLA-F, is the only nonconservative amino acid change between the groove of human and chimpanzee HLA-F. Modeling the selective pressure acting on the HLA-F gene in primates with a PRoperty Informed Model of Evolution (PRIME) using the Conant-Stadler amino acid categories (Conant et al., 2007) suggested the strong change in polarity of the R62W substitution was positively selected whereas other positions in the groove have remained constant over time via purifying selection (Table S4 ). Mutation of W62 to the ancestral R (W62R) almost completely abolished peptide binding. Only 53 peptides were eluted and identified by LC-MS from W62R HLA-F, which was expressed and purified from 293T cells in the same manner as WT ( Figure 4C ). This reduction was seen in both the diversity of peptides (98% reduction) and the total quantity of peptide bound (90% reduction) as represented by the summed ligand intensity for all eluted peptides. Considering that the R62W substitution exists only in human and orangutan HLA-F, it is likely that other primate versions of HLA-F lack peptide presentation. Other substitutions among primate versions of HLA-F may also be functionally important, such as those on the right side of the groove that may alter the KIR footprint ( Figure 4B ).
High-Affinity Recognition of b 2 m-HLA-F by LIR1 Is Mediated via a Docking Strategy Shared with the Viral UL18 MHC Mimic We used Blitz biolayer interferometry (BLI) to measure interactions between HLA-F and the inhibitory NKR, LIR1. Previous studies characterizing this interaction utilized empty b 2 m-HLA-F produced through refolding of E. coli-generated inclusion bodies and did not report affinity measurements (Lepin et al., 2000) . For our binding experiments, we produced HLA-F OCs through refolding and peptide-loaded b 2 m-HLA-F in 293T or Hi5 cells and LIR1 D1-D2 was also made in Hi5 cells. While LIR1 does not bind HLA-F OCs with a measureable affinity ( Figure S4A ), it recognizes peptide-bound b 2 m-HLA-F with an equilibrium K D of 2 mM ( Figure 5B ), which makes b 2 m-HLA-F the highest-affinity ligand for LIR1 among the human MHC-I molecules (affinities range from 15 to 100 mM) (Chapman et al., 1999) .
To investigate the molecular details of this interaction, we crystallized and solved the complex structure of LIR1 bound to HLA-F ( Figure 5A ). The structure revealed that LIR1 adopts a highly conserved docking orientation on the side of the b 2 m-HLA-F complex that was also seen in the existing HLA-A2-LIR1 (Willcox et al., 2003) , UL18-LIR1 (Yang and Bjorkman, 2008) , and HLA-G-LIR2 (Shiroishi et al., 2006) complex structures ( Figure 5C ). The HLA-F-LIR1 interface has 1,700 Å 2 total solvent-accessible surface area buried, which is nearly identical to that of the HLA-A2-LIR1 interface and less than the 2,200 Å 2 UL18-LIR1 interface. Owing to the docking orientation of LIR1 on the side of HLA-F away from the peptide-presenting groove, the affinity of LIR1 for the ancestralized W62R b 2 m-HLA-F is only slightly reduced ( Figure S4B ). This result is in agreement with previous reports that MHC-LIR ligation is not directly dependent on interactions with peptide (Willcox et al., 2003) , although See also Figure S2 and Table S2. peptide is required for stable surface expression of the mature b 2 m-MHC-I-peptide complex (Blum et al., 2013) . The interactions between MHC-I and LIR1 can be separated into two separate interfaces; the interface where the D1-D2 hinge region contacts b 2 m (site 1) and the interface where residues of the MHC-I a3 domain are recognized by the LIR1 D1 domain (site 2) ( Figure 5A ). The site 1 interface is entirely conserved in LIR1 recognition of MHC-I family members, which may explain why LIR1 binding to HLA-F OCs is greatly reduced. While there are some amino acid differences between the a3 domain of HLA-F and HLA-A2 at the site 2 interface, these changes don't greatly alter the chemical properties of the residues (i.e., I200 versus V200). A conformational change in the UL18 binding loop of LIR1 (which is mostly unstructured in the HLA-A2-LIR1 complex) allows it to engage the tip of the a3 domain of HLA-F via two salt bridges (HLA-F D196-LIR1 R84 and HLA-F E229-LIR1 K41), two hydrogen bonds (HLA-F D196-LIR1 D80 and HLA-F P193-LIR1 T43), and numerous van der Waals contacts (Figures 5A and S5; Table S5 ). These additional contacts are reminiscent of high-affinity LIR1 recognition of the viral MHC mimic, UL18 ( Figure 5C , right inset). Adoption of this modified recognition strategy might explain why LIR1 , HLA-B*07:02 (orange) , HLA-E*01:03 (green) (Kraemer et al., 2015) , HLA-DQ7.5 (gray) (Bergseng et al., 2015) . (B) Observed motif of HLA-F peptides grouped by representative lengths: 9-mers (left), 11-mers (middle), 13-mers (right). (C) List of stanniocalcin 2-originating phosphorylated peptides eluted from HLA-F aligned to the C-terminal sequence of stanniocalcin 2. See also Table S3 and Figure S3 . has a greater affinity for b 2 m-HLA-F than any other MHC-I molecule measured.
Peptide Binding Prevents HLA-F Recognition and Triggering of KIR3D
In order to assess whether peptidebound HLA-F can bind to and trigger signaling of KIRs previously shown to recognize HLA-F OCs, we employed a Jurkat reporter cell (JRC) system. To this end, we used b 2 m-deficient Jurkat cells stably transduced with KIR chimeric constructs (KIRz) containing the extracellular and transmembrane domain of the KIR of interest and the cytoplasmic domain of CD3z. This allows for measurement of CD69 expression as an activation marker after functional ligation of the transduced KIR ( Figure 6C ). For KIR3DS1 and KIR2DS4, we used the transmembrane domain of KIR3DL1 to ensure stable cell-surface expression independent of the DAP12 adaptor protein. We confirmed surface expression of KIRz on Jurkat cells via antibody staining ( Figure 6D) . Reporter cells were then incubated with cell-sized beads coated with biotinylated monomers of HLA-F. Antibody-mediated crosslinking of KIRz-JRC served as a positive control whereas streptavidin beads coated with free biotin and JRCs expressing an irrelevant KIRz (KIR2DL3) were used as negative controls.
Upon bead binding, granularity of the JRCs increased substantially, which allowed for discrimination of bead-bound from unbound cells. HLA-F OC beads bound to KIR3DS1z-JRC and KIR3DL2z-JRC to a similar extent as beads coated with their respective anti-KIR antibodies ( Figure 6A ) and triggered activation in line with previous findings ( Figure 6B ) (Garcia-Beltran et al., 2016) . Beads coated with peptide-bound HLA-F produced in 293T or Hi5 cells did not bind or activate KIR3DS1z-JRC or KIR3DL2z-JRC. In addition, our findings suggest that HLA-F is not a ligand for the activating KIR2DS4 as no binding or HLA-F-mediated triggering was detected with KIR2DS4z-JRC. This was irrespective of HLA-F peptide status and contrary to what was previously reported (Goodridge et al., 2013) . Overall, these results suggest that unlike HLA-F OCs, peptide-bound HLA-F is not a ligand for KIR3DS1 and KIR3DL2 and perhaps, peptides directly hinder HLA-F-KIR ligation.
Tetramers Composed of HLA-F Loaded with Endogenous Peptides or HLA-F OCs Differentially Stain Leukocytes To explore potential receptors that might be responsive to peptide-loaded HLA-F ex vivo, we made tetramers from HLA-F protein produced in 293T cells. We compared peripheral blood mononuclear cell (PBMC) staining of these tetramers with those made from HLA-F expressed in Hi5 cells (which is bound with insect peptides) or HLA-F OCs (which is empty and lacking b 2 m) and drew tetramer + gates using our negative control T22 tetramers. Fresh PBMCs obtained from four healthy volunteers were stained with a panel of lymphocyte and monocyte markers as well as antibodies detecting LIR1, KIR3DS1-L1, and KIR3DL2 before tetramer staining. LIR1 expression on a wide range of leukocytes was consistent with previous reports (Colonna et al., 1997) ; 8%-53% of CD56 + CD16 + NK cells, 4%-8% of CD3 + T cells, 75%-95% of B cells, and nearly all monocytes express LIR1 ( Figure S6 ). KIR3DS1-L1 expression on NK cells (10%-35%) and T cells (.7%-2%) was also consistent with previous studies (O'Connor and McVicar, 2013) , but surprisingly, KIR3DL2 expression could not be detected in our donor pool.
Tetramer staining of PBMCs revealed that HLA-F tetramers consistently stained a broad array of cell types and that peptide presentation has a dramatic effect on the staining profile. Peptide-bound 293T tetramers stained a statistically significant greater proportion of T cells (2.5-fold), NK cells (4-fold), and monocytes (4-fold) than HLA-F Hi5 tetramers (Figure 7) . The HLA-F OC tetramers do not markedly stain T cells. However, consistent with interactions with NKRs, HLA-F OC tetramers stained a greater proportion of B cells (3-fold) and NK cells (2-fold) compared to Hi5 tetramers. Although not statistically significant, the data also show a clear trend for greater 293T tetramer staining of T cells and NK cells compared to OC tetramers, suggesting that recognition is enhanced when HLA-F is loaded with peptides of human origin. It seems that a substantial portion of the tetramer staining with 293T and OC HLA-F cannot be attributed to interactions with known HLA-F binding partners, as LIR1 + T cells and KIR3DS1-L1 + NK cells show only slightly greater tetramer staining ( Figure S6C ). Therefore, this increase in tetramer staining may be due to interactions with unexplored HLA-F receptors, such as TCRs and KIRs, that sense peptidedependent changes in HLA-F surface epitopes.
DISCUSSION
Prior to this study, it was unclear whether HLA-F presented antigen, despite its strong resemblance to other members of the MHC-I family and painstaking efforts to address this question. Structural biology has allowed us to peer into the groove of HLA-F and visualize the molecular landscape that has been remodeled through evolution for a specialized mode of peptide presentation. The extra electron density we see in the antigenbinding groove of HLA-F is reminiscent of what Bjorkman and Wiley reported when they solved the first structure of an MHC molecule (Bjorkman et al., 1987) . However, HLA-F evolved substitutions in the groove that have molded it into an open-ended cleft capable of presenting long peptides that extend up and out of the groove. One substitution, R62W, which arose separately in the human and orangutan lineages, imparts HLA-F with the ability to present these noncanonical peptides, allowing for a dramatic change in function over a relatively short period of time.
This study motivates further examination of the biochemical and functional transformation of the HLA-F groove in primate evolution. What is the most ancient, functionally significant HLA-F ortholog and in what context did it regulate immunity, via antigen presentation or another means? Throughout primate evolution, pregnancy has progressively become more invasive and immunologically complex (Coe and Lubach, 2014; Carter et al., 2015) . The distinct expression pattern of HLA-F (Shobu et al., 2006; Hackmon et al., 2017) and its ability to regulate NK cells which govern the remodeling of the fetal-maternal interface indicate a role for HLA-F during gestation. Future studies will supplement the abundant observational evidence that HLA-F plays a critical role in pregnancy by providing mechanistic insight into how and through which NKRs HLA-F regulates gestational immunity.
Previous studies attempting to elute canonical peptides from HLA-F have relied upon purified, native HLA-F from unstimulated, uninfected cell lines where surface expression is tightly regulated and HLA-F is predominately intracellular and empty (Wainwright et al., 2000) . Protein engineering and recombinant expression strategies allowed us to capture HLA-F in a peptide-receptive state that may be, to a greater extent, free from regulatory checkpoints for antigen loading and trafficking. This enabled us to examine large quantities of HLA-F for evidence of peptide presentation and allowed for the confident identification of unconventional peptides that may have been previously overlooked due to their large size (Goodridge et al., 2010 ).
Though we have clearly shown that HLA-F can present peptide, the mechanism of peptide loading and functional consequences of peptide presentation require further study. The role of the open-ended groove of HLA-F that causes extension of Table S5. the N-terminal portion of HLA-F peptides is also unclear and future studies will determine whether these extended peptides are engaged by antigen receptors. Another unexplained facet of HLA-F peptide presentation is the prevalence of PTMs on peptides eluted from HLA-F. Could these chemically altered residues substantially influence the epitopes seen by antigen receptors and has HLA-F evolved a groove that is particularly well suited for presenting phosphorylated peptides? This notion is evocative of peptide presentation by the rodent MHC molecule, H2-M3, which has a groove that is specialized for presenting bacterial N-formyl peptides (Wang et al., 1995) .
Our Jurkat reporter assay validated previous reports that HLA-F OCs are a ligand for KIR3D and demonstrate that HLA-F OCs and peptide-bound HLA-F have distinct NKR binding partners. This indicates that peptide binding directly obstructs HLA-F recognition by KIR3D or alters the anatomy of the HLA-F groove and the molecular epitopes seen by NKRs. Like TCRs, NKRs can be highly sensitive to presented peptides; KIR3D are generally justify further exploration of antigen-specific recognition of HLA-F by TCRs and NKRs. However, the broad staining of leukocytes by peptide-loaded and OC tetramers suggests that the bulk of receptors that engage HLA-F are not particularly reliant on peptides and are highly conserved across cell types and donors, such as the LIRs. Consistent with an extensive immunoregulatory role, LIR1 recognition of MHC-Ia and HLA-G inhibits the cytotoxicity and activation of NK cells and other leukocytes in a variety of settings (Colonna et al., 1997; Favier et al., 2010) . In HLA-F recognition, the highly conserved MHC-I-LIR footprint is supplemented with an additional interaction interface that is also seen in the UL18-LIR1 complex structure. We propose that the enhanced affinity of LIR1 for HLA-F can be attributed to this additional contact site that is absent in other examples of LIR1-MHC-I recognition. Our thermal denaturation assays show that HLA-F OCs, with a Tm of 52 C, are thermo-stable compared to other empty MHC-I molecules tested previously (Tm range 40 C-45 C) (Strong et al., 2003) . The ability to exist in an OC and peptide-bound state equips HLA-F with an additional layer of regulatory potential that is unique in the MHC-I family. However, it is unclear what regulates the switching of HLA-F from an OC to a peptide-bound state. Is it the availability of ligand, as is the case for other members of the MHC-I family (Lee et al., 1998) or could environmental conditions, such as changes in pH that occur during infection or inflammation, modulate the conformation of HLA-F on the cell surface? Further study is needed to describe the molecular architecture of MHC-I OCs and how they are recognized by NKRs. Elucidation of this mechanism will be a critical step toward understanding how KIRs can engage peptide-bound MHC-Ia molecules as well as HLA-F OCs. Perhaps cell-surface association with MHC-Ia molecules, with or without peptide, plays an important role in HLA-F OC recognition (Goodridge et al., 2010) .
Evidence is mounting that HLA-F signaling through NKRs regulates the immune system in pregnancy, infection, and autoimmunity. Until recently, our understanding was limited of the underlying structural and biochemical properties that govern HLA-F function. The data presented in this study have changed our general understanding of the evolution of antigen presentation within the context of the MHC. Our results provide a blueprint of the molecular details of HLA-F, which will inform future exploration of its roles in human health and allow for the development of additional, targeted therapeutics.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects Samples of peripheral blood were obtained from healthy volunteers under protocols approved by the ethical committees of the University of Chicago (IRB13-0666). The cohort was composed of two male and two female donors aged 24-30 years.
Cell lines
Sf9 insect suspension cells (Spodoptera frugiperda, female, ovarian) grown in Sf-900 II SFM supplemented with heat-inactivated FBS (to 10%), L-glutamine (to 1%) and Gentamicin Sulfate (.01 mg/mL) were used for production of baculovirus. High Five insect suspension cells (Trichoplusia ni, female, ovarian) grown in Insect-XPRESS Protein-free Insect Cell Medium supplemented with L-glutamine (to 1%) and Gentamicin Sulfate (.01 mg/mL) were used for protein production. All insect cell cultures were grown at 27 C with 120 rpm shaking. Human embryonic kidney HEK293T adherent cells were grown at 37 C in 5% CO 2 in culture medium composed of Advanced DMEM, 2% heat-inactivated ultra-low Ig FBS, Antibiotic/Antimycotic and 2mM L-glutamine. The Jurkat cell line (clone E6.1) was cultured at 37 C in 5% CO 2 in RPMI-1640 containing L-glutamine supplemented with 20% FBS Superior and 1 mg/ml Puromycin. Bacteria E. coli BL21(DE3), DH5a and Rosetta(DE3) pLysS were cultured at 37 C, shaking at 250 rpm.
METHOD DETAILS
Cloning, protein expression and purification For Hi5 insect cell and 293T expression, the extracellular portion of the mature HLA-F protein (Gly1-Ile284) was fused to b 2 m (Ile1-Met99), as described previously (Godeau et al., 1992) For BLI measurements and tetramer production, HLA-F constructs and LIR1 D1-D2 were cloned into vectors containing a BirA biotinylation sequence (Avitag) upstream of a 3C protease site and 8x his-tag (GLNDIFEAQKIEWHE-GGSG-LEVLFQGP-HHHHHHHH). For production of refolded HLA-F OC and b 2 m-HLA-F, the extracellular portion of HLA-F (Gly1-Ile284) and b 2 m (Ile1-Met99) were separately cloned in frame with methionine start codons in the pET28a vector. Bacterial inclusion bodies were generated in E. coli BL21(DE3) and Rosetta(DE3) pLysS and refolded essentially as described previously (Garboczi et al., 1992; with omission of peptide.
Hi5 cells were grown in 1 L volumes in 2.4 L flasks and transduced with high titer recombinant baculovirus (P2) stock generated in Sf9 cells at a 1:1000 dilution. 72 hr after infection, the culture media was collected and his-tagged protein secreted into the media was extracted via overnight (O/N) batch binding at 4 C with Nickel agarose (nickel-nitrilotriacetic acid (NTA)) in the presence of 20 mM imidazole, pH 7 to reduce non-specific binding. Proteins were eluted with 200 mM imidazole, pH 8 in HBS, buffer exchanged to HBS buffer via disposable desalting columns and incubated with 3C protease (1:100) for cleavage of his-tags O/N at 4 C. HBS buffer is composed of 10 mM HEPES, pH 7.2, 150 mM NaCl and 0.02% NaN3. Proteins were further purified by Superdex S200 size-exclusion chromatography FPLC in HBS buffer. Refolded protein was purified similarly via Ni-NTA and size exclusion chromatography in HBS buffer. Protein concentration was initially determined by BCA and matched A 280 measurements using theoretical extinction coefficients (calculated by the ExPASy Protparam tool). For immobilization on streptavidin biosensors, the Avitag constructs were biotinylated with BirA biotin protein ligase in the presence of biotin, and subsequently purified via size exclusion chromatography. The HLA-F W62R mutant was cloned by overlapping PCR using the WT construct as a template and was purified similarly. For crystallization, peak fractions of b 2 m-HLA-F were concentrated to 6 mg/mL and peak fractions of LIR1 were concentrated to 3 mg/mL. For HLA-F-LIR1 complex formation, HLA-F and LIR1 were mixed at a 1:1 molar ratio and incubated at room temperature for 1 hr before being concentrated to 7.5 mg/mL.
Crystallization and structure determination b 2 m-HLA-F at 6 mg/mL was crystallized using hanging drops at 20 C by mixing 1:1 or 1.4:1 with mother liquor (ML) containing 27% PEG 10,000 and 0.1 M Tris, pH 8.5. HLA-F-LIR1 at 7.5 mg/mL was crystallized via hanging drops by mixing 1:1 or 1.4:1 with ML containing 27% PEG 550 MME, 0.1 M Tris, pH 7 and 300 mM NaCl. Crystals were cryo-cooled in ML supplemented with 10%-20% (v/v) glycerol, 10%-20% (v/v) ethylene glycol or 35% PEG 550 MME before data collection. The b 2 m-HLA-F datasets were collected on a MAR300 CCD detector at beamline 23 ID-B and the b 2 m-HLA-F-LIR1 datasets were collected on a Dectris Pilatus3 6M detector at beamline 23 ID-D at the Argonne National Laboratory Advanced Photon Source. Datasets were processed with xia2 (Winter, 2010) and solved by molecular replacement with the program Phaser (McCoy et al., 2007) using the following search models for each structure: HLA-F -PDB: 1HSA (Madden et al., 1992) and HLA-F-LIR1 -PDB: 1P7Q (Willcox et al., 2003) . For both structures, Phenix (Adams et al., 2010) was used for initial rigid body refinement and then for subsequently restrained refinement of individual sites and B-factors. Non-crystallographic restraints were applied for the HLA-F structure as there are four copies of b 2 m-HLA-F in the asymmetric unit. Between refinement cycles, manual model building was performed with COOT (Crystallographic Object-Oriented Toolkit). Ligand-placing was guided by 2F o -F c , F o -F c and composite omit maps generated with Phenix. Analysis of buried surface Evolutionary analyses of Primate HLA-F genes We identified primate HLA-F genes from gene and genome databases using a reciprocal BLAST strategy. Specifically, we used the human HLA-F gene as a query to BLAT search the Neanderthal, Denisovan, chimpanzee (CHIMP2.1.4), gorilla (gorGor3.1), orangutan (PPYG2), gibbon, (Nleu1.0), rhesus monkey (MMUL_1), hamadryas baboon (Pham_1.0), olive baboon (Panu_2.0), vervet monkey (ChlSab1.0), marmoset (C_jacchus3.2.1), Bolivian squirrel monkey (SalBol1.0), tarsier (tarSyr1), mouse lemur (micMur1), and galago (OtoGar3) genomes. HLA-F genes were not identified in the marmoset, Bolivian squirrel monkey, tarsier (tarSyr1), mouse lemur, or galago genomes indicating it is specific to Old World monkeys. We used the default settings in MUSCLE (implemented in Genious 6.1.2) to align primate HLA-F genes and the suite of analyses methods implemented in DataMonkey to quantify the strength and direction of selection acting on primate HLA-F genes. We identified the best-fitting model of nucleotide substitution for our alignment using Datamonkey, then we used the PRIME method to test for evidence of positive selection involving changes in amino acid properties.
Biolayer Interferometry Measurements
All BLI measurements were performed using a Blitz instrument at room temperature (22 C). Biotinylated LIR1 protein was immobilized on streptavidin sensors until saturation. Dilutions of HLA-F, HLA-F OC and W62R HLA-F from 0.5 -42 mM were made in HBS. A HBS-only trace was subtracted from HLA-F measurements. Equilibrium dissociation constants were determined by nonlinear regression with Prism software using a shared Bmax given comparable immobilization of ligands.
Production of Jurkat reporter cells b 2 m-deficient Jurkats were previously generated via Cas9-mediated deletion and subsequently transduced with KIRz chimeric constructs via lentiviral gene transfer as described previously (Garcia-Beltran et al., 2016) . KIRz chimeric receptors for the inhibitory KIR2DL3z (Allele KIR2DL3*001) and KIR3DL2z (Allele KIR3DL2*001) contain the respective extracellular domain (ECD) and transmembrane domain (TMD) fused with the cytoplasmic tail of the human CD3z chain comprising the triple immune tyrosine activating motif (ITAM). KIR3DS1z (Allele KIR3DS1*013) and KIR2DS4z (Allele KIR2DS4*001) were designed by fusing the respective ECD with the TMD of the inhibitory KIR3DL1 and the cytoplasmic tail of the CD3z chain. Constructs were ordered from GeneArt and cloned into a lentiviral transfer vector containing an SFFV promoter and IRES-driven puromycin resistance (kindly provided by Thomas Pertel). Lentiviral supernatant was obtained via three-plasmid lipofectamine transfection of 293T cells with psPAX2, pHEFVSV-G and the transfer vector (pLVX-SFFV-KIRz-IRES-Puro). Transduced cells were selected in culture media with Puromycin and sorted for KIR expressing CD3 + cells via fluorescence-activated cell sorting. Cells were cultured in RPMI-1640 containing L-glutamine, supplemented with 20% FBS Superior and 1 mg/ml Puromycin. KIR expression was assessed by staining with the following antibodies: anti-KIR3DS1-L1, anti-KIR3DL2-L1, anti-KIR2DL2-3 and anti-KIR2DS4.
Jurkat Reporter Cell Assay
Streptavidin-coupled beads were coated with biotinylated KIR-antibodies (anti-KIR3DS1-L1 clone REA168, Miltenyi, anti-KIR2DS4 clone JJC11.6, Miltenyi, anti-KIR2DL3 clone REA147, Miltenyi, anti-KIR3DL1-L2 clone 5.133, Miltenyi), free biotin and biotinylated HLA-F monomers for 1 hr at 4 C while rotating. 1 mg of antibody per 0.1 mg of beads, and biotinylated HLA-F monomers were coated at 110 pmol per 0.1 mg beads. Negative control beads were saturated with free biotin. 2.53104 KIR2DL3z, KIR2DS4z, KIR3DS1z, or KIR3DL2z -JRC were co-incubated with 5 ml of HLA-F monomer coated beads diluted in 50 ml PBS; with 1 ml of biotin-coated beads in 10 ml PBS as a negative control; with 0.5 ml of anti-KIR-coated beads in 5 ml PBS as a positive control or without beads as a blank control (background) for 5 hr at 37 C. Subsequently, cells were stained with anti-CD3 and anti-CD69 antibodies, washed and fixed with PBS/4% paraformaldehyde. Flow cytometry data were acquired with a BD FACS Canto II and analyzed using FlowJo software version 10.2. Percentages of bead binding cells and CD69
+ cells are shown with display of median and interquartile range after subtraction of background (blank control). Data is derived from three independent experiments.
PBMC tetramer staining
PBMCs were purified via ficoll-gradient from healthy volunteers and used immediately for tetramer staining. PBMCs were incubated with 600 nM tetramer in blocking buffer for 45 min at room temperature in the dark. Blocking buffer is composed of sterile PBS, 3% FBS, 10% human serum and 0.02% NaN 3 . PBMCs were then washed and incubated with antibodies for 30 min on ice in the dark. PBMC wash buffer is composed of PBS, 3% FBS and 0.02% NaN 3 . After additional washes, PBMCs were analyzed on a BD LSR Fortessa. Tetramer staining data was analyzed with FlowJo software. Compensation beads were used to set voltages and perform compensation while isotype control antibodies were used to set NKR + gates. Tetramer positive gates were drawn with T22 negative control tetramers at 1% + . Graphs were made and statistical significance analysis was performed with Prism software.
QUANTIFICATION AND STATISTICAL ANALYSIS
Information on the statistical tests used can be found in the Results and Figure Legends . Statistical analysis was performed with Prism software. For PBMC tetramer staining statistical significance analysis ( Figure 7B) , we compared the percentages of tetramer positive cells between tetramer types via the nonparametric Friedman test with the repeated-measures test to incorporate donor to donor variability (as in a pairwise t test) and Dunn's multiple comparison post hoc test. * denotes significant (P value of 0.01-0.05).
DATA AND SOFTWARE AVAILABILITY
The structural data reported in this study were deposited in the Protein Data Bank under accession codes PDB: 5IUE (HLA-F structure) and PDB: 5KNM (HLA-F-LIR1 complex structure). The data on peptides eluted from WT and W62R HLA-F expressed in 293T cells can be found in Table S3 . In accordance with the integrity of data policy of the Heinrich Pette Institute (HPI), all primary data from in vitro experiments have been submitted to the Heinrich-Pette Institute (HPI) data repository. Data are available from the HPI data repository upon request for researchers who meet the criteria for access to confidential data.
